

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 27 June 2018, its subsidiary, Nanjing Legend Biotech Co., Ltd. (“**Nanjing Legend**”), has entered into a cooperation agreement with The Affiliated Sir Run Run Hospital of Nanjing Medical University* (南京醫科大學附屬逸夫醫院) (“**Affiliated Hospital of Nanjing Medical University**”), whereby Nanjing Legend and Affiliated Hospital of Nanjing Medical University agreed to cooperate on, among others, the clinical trial and scientific research in relation to CAR-T immuno-cell therapy (the “**Cooperation Agreement**”). The aforesaid cooperation with Affiliated Hospital of Nanjing Medical University is one of the first steps in developing the CAR-T business of the Group and will prepare for the commercialization of the Group’s CAR-T products in the future.

THE COOPERATION AGREEMENT

Under the Cooperation Agreement, Affiliated Hospital of Nanjing Medical University and Nanjing Legend agree to cooperate on the following matters, including clinical trial and scientific research in relation to CAR-T immuno-cell therapy:

Joint establishment of a cell immunotherapy clinical research centre (the “**Clinical Research Centre**”)

Affiliated Hospital of Nanjing Medical University will be responsible for the infrastructure establishment and Nanjing Legend will be responsible for, amongst others, the training of staff and providing technical support.

Cooperation on clinical trial	The Clinical Research Centre will, through the Affiliated Hospital of Nanjing Medical University, make its application for the relevant qualification as a national clinical trial institution for new drugs, which will allow priority to be given to the clinical trials of other CAR-T cell therapy products developed by Nanjing Legend, upon the relevant qualification being granted.
Cooperation on immunotherapy	Subject to the grant of approval by the relevant regulatory bodies of Nanjing Legend's CAR-T cell therapy products to be put on the market, and upon the certification of the Clinical Research Centre, Nanjing Legend will prioritize the provision of CAR-T cell therapy products for the patients of the Clinical Research Centre.
Cooperation on scientific research	The research papers in relation to the scientific research findings on, among others, carrying out clinical trials and clinical treatments in relation to CAR-T immuno-cell therapy, jointly composed by Affiliated Hospital of Nanjing Medical University and Nanjing Legend will be submitted to internationally renowned academic journals.
Cooperation on applications to governmental authorities	Using the Clinical Research Centre, Affiliated Hospital of Nanjing Medical University and Nanjing Legend will apply to relevant governmental authorities for certifications and other recognitions, honours and governmental subsidies.

INFORMATION ON AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY

Affiliated Hospital of Nanjing Medical University is a provincial level public hospital jointly established by Nanjing Medical University and Jiangning District People's Government funded by The Shaw Prize Foundation and is approved by the Ministry of Education. It is a comprehensive teaching hospital built with Grade III A and international JCI certification standard, which provides medical, education, scientific research and service management services.

INFORMATION ON THE GROUP AND NANJING LEGEND

The Group is principally engaged in the provision of (i) bio-science services and products, (ii) industrial synthetic biology products, and (iii) precision immune-cell therapy.

Nanjing Legend is a limited liability company incorporated in the People's Republic of China and is a subsidiary of the Company.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate to deal in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 28 June 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*